





## Number of HSCT for autoimmune diseases : 2609 EBMT Registry - February 2018

Transplant procedures	2609	
Patients	2553	
Male/Female %	39/61	
Paediatric/ adult / %	10/90	
Centres /Countries	267/ 40	
Overall follow up (median, Yr HSCT < 2017)	3y (<1-22)	
	Autografts n=2444	Allografts n=165
First	2420	133
Second	20	25
Third	1	7
Median age at 1st transplant	38y (1-76)	12y (<1-67)

► MULTIPLE SCLEROSIS	1187	► HAEMATOLOGICAL	104
► CONNECTIVE TISSUE	690	ITP	31
SSc	520	AIHA	26
SLE	116	Evans'	22
PM-DM	17	Other	26
Sjogren	3	► VASCULITIS	55
Antiphosph. Syndrome	5	Wegener's	14
Other/Unknown	29	Behcet's	11
► ARTHRITIS	186	Takayasu	2
Rheumatoid arthritis	82	Polyarteritis	4
Juvenile chronic arthritis :		Churg-Strauss	2
*Systemic JIA	59	Other/Unknown	22
*Other JIA	18	► OTHER NEUROLOGICAL	105
*Polyarticular JIA	17	NMO	25
Psoriatic arthritis	3	CIDP	46
Other	7	Myasthenia gravis	7
► INFLAMMATORY BOWEL	209	Other/Unknown	27
Crohn's disease	176	► INSULIN DEPENDENT	20
Ulcerative colitis	4	DIABETES	
Other	29	► OTHER	52



### Non-interventional prospective studies

- 1- NISSC I : Now closed. Recruited 82 patients from 12 centres / 7 countries. The study will be presented during the Oral session 2 : AA and ADs, 21 March, 9am, room 5B.
- 2- OMST: Multiple sclerosis patients treated with auto-HSCT (R Saccardi, Florence, Italy)
- 3- NISSC II: Post transplant management of SSc patients treated with auto-HSCT (D Farge, Paris, France)

### Education

- 1- Updated recommendations for cardiopulmonary evaluation, screening, patient selection for stem cell therapy in poor prognosis systemic sclerosis.
- 2- Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's Disease: a review on behalf of ECCO and EBMT
- 3- ADWP / IEWP joint Educational Meeting, Newcastle, UK, 3-5 November 2017, where we explored the interface between autoimmunity, autoinflammatory disease, Immunodeficiency and other inherited disorders
- 4- ADWP / SAAWP joint Educational Meeting, Florence, Italy, 15-17 November 2018 – SAVE THE DATE!

### ADWP – Recent publications

- 1- Evolution, trends, outcomes and economics of HSCT in severe autoimmune diseases. Snowden J, *Blood Adv.* 2017 Dec 20;1(27):2742-2755
- 2- Autologous HSCT in severe Crohn's Disease: a review on behalf of ECCO and EBMT. Snowden J, Panes J, E Ricart, *J Crohns Colitis.* 2018 Jan 8.
- 3- Autologous SCT in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. Lindsay JO, *Lancet Gastroenterol Hepatol.* 2017 Jun;2(6):399-406.
- 4- Cardiopulmonary assessment of patients with systemic sclerosis for HSCT: recommendations from the EBMT ADWP and collaborating partners. Farge D, *Bone Marrow Transplant.* 2017 Nov;52(11):1495-1503
- 5- Autologous HSCT for pediatric multiple sclerosis: a registry-based study of the ADWP/PDWP (EBMT). Burman J, *Bone Marrow Transplant.* 2017 Aug;52(8):1133-1137.
- 6- Long-term Outcomes After Autologous HSCT for Multiple Sclerosis. Muraro P, *JAMA Neurol.* 2017 Apr 1;74(4):459-469
- 7- Autologous HSCT for systemic lupus erythematosus: time ready for a paradigm shift? T Alexander, *Clin. Exp. Rheumatol.* 2017 35, 359–361

### Key scientific advances

- Over 2500 HSCT for autoimmune diseases in the largest database worldwide
- In association, the ADWP continues to add to the evidence-base with prospective studies, registry-based studies and guidelines written with other professional groups outside of Haematology. Our collaborations also now robustly extend outside of Europe, including North and South America and Australia.
- The clinical efficacy of autologous HSCT for some indications AD is now becoming well established. The future challenge is to further optimize transplant protocols to maximize safety and efficacy of this procedure. Health economic considerations and implementation science will also be essential to define how to deliver HSCT best in the context of biological and other modern therapies. Immunologic studies in the field are ongoing and provide novel aspects in the understanding of the underlying mechanisms that promote long-term drug-free remissions by HSCT in ADs.
- Sustained positive clinical results and enhanced ADWP activity in otherwise refractory AD patients continues to attract patients, clinicians, and healthcare providers in the field. However, the future of this treatment will depend on quality care. We continue to update guidelines for HSCT in specific autoimmune disease groups and delivery of HSCT in AD by JACIE accredited centres.
- **AUTOIMMUNE DISEASES ARE THE FASTEST GROWING INDICATION FOR HSCT IN THE EBMT ACTIVITY SURVEY (Passweg et al, *Bone Marrow Transplantation*, 2018).**